EU agency backs Novo's new insulin, Lilly imaging agent
LONDON Oct 19 (Reuters) - Novo Nordisk's ultra long-lasting insulin Tresiba has been recommended for approval for the European Medicines Agency in an important boost for the Danish drugmaker's key new product.
The European endorsement, announced by the London-based agency on Friday, comes after the treatment hit regulatory delays in the United States.
Tresiba, or degludec, is central to Novo's aim of ending Sanofi's dominance of the long-acting insulin market.
The regulator also recommended a new Alzheimer's imaging agent from Eli Lilly, the first radiopharmaceutical for PET imaging of beta-amyloid plaques, which are found in the brains of patients with the disease.
- Atheists face death in 13 countries, global discrimination: study
- Missouri executes man for killing good Samaritan motorist in 1994
- Focus turns to Thai military, anti-government protesters tell them to pick sides
- Google executives' planes saved millions in costs due to error - NASA
- Apple scores legal victory over Samsung in South Korea